Skincare while pregnant: which actives are safe, which to avoid, and what we simply don't know

All topical retinoids — retinol, retinaldehyde (retinal), tretinoin (retinoic acid), retinyl palmitate, retinyl acetate, and hydroxypinacolone retinoate (HPR/Granactive Retinoid) — are recommended against during pregnancy and while planning to conceive. This recommendation is precautionary rather than based on demonstrated harm at cosmetic topical doses, but it is consistent across dermatology guidelines and regulatory bodies. The reasoning has three pillars. First, oral synthetic retinoids (isotretinoin, acitretin) are among the most potent human teratogens known, causing cranial neural crest defects and other fetal abnormalities with near-certainty at therapeutic doses. Second, high-dose supplemental oral preformed vitamin A (above 10,000 IU/day) has been associated with increased cranial neural crest birth defects in one large epidemiological study. Third, although topical retinoid absorption is low, it is not zero — the precautionary principle applies when potential consequences are severe and irreversible. The reassuring side: the evidence base for harm from topical retinoids specifically is limited. A prospective multicenter study of 235 first-trimester topical retinoid exposures found no increase in birth defect rates versus controls. A large Nordic registry study of 3.8 million births found no statistically significant increase in major congenital malformations from first-trimester topical retinoid exposure (aRR 1.1, 95% CI 0.87–1.38). Despite these findings, current clinical guidance remains: avoid topical retinoids during pregnancy and while planning to conceive. Stop retinol, retinal, tretinoin, and retinyl ester products and discuss timing with your obstetrician.

• Study High preformed vitamin A supplementation (>10,000 IU/day) during early pregnancy was associated with a 4.8-fold increased prevalence of cranial neural crest birth defects compared to ≤5,000 IU/day; the threshold appeared near 10,000 IU/day of supplemental vitamin A. ¹
• Study A prospective multicenter study of 235 pregnancies with first-trimester topical retinoid exposure found no significant differences in rates of spontaneous abortion or birth defects vs controls, and no case of retinoid embryopathy; authors nonetheless concluded topical retinoids should not be recommended during pregnancy given uncertain risk-benefit. ²
• Study A Nordic registry cohort study of 3.8 million births (1996–2020) found no statistically significant increase in major congenital malformations in infants exposed to topical retinoids in the first trimester (3.3% vs 3.0%; aRR 1.1, 95% CI 0.87–1.38). ³

One honest caveat The evidence of actual harm from topical retinoids at cosmetic doses is limited — two large studies found no statistically significant increase in birth defects. The avoidance recommendation is precautionary, not a confirmed-harm determination. That said, precaution is entirely appropriate given what we know about systemic retinoid teratogenicity and the impossibility of ruling out low-level risk with available data.

The following actives are broadly regarded as compatible with pregnancy based on low systemic absorption, well-established safety records, or specific pregnancy study data. None has been tested in controlled trials with pregnant women as the primary population — that standard of evidence does not exist for any topical cosmetic active. Always confirm with your obstetrician. **Azelaic acid** is one of the very few topical actives where dermatologists and obstetricians broadly reach for an affirmative safe-use position during pregnancy, not just a low-risk one. It is a naturally occurring dicarboxylic acid already present in human plasma from dietary sources and skin microbiome metabolism; approximately 4% of the topical dose is systemically absorbed, and that absorbed amount falls within the normal physiological range. It was historically classified as FDA Pregnancy Category B (animal studies showed no fetal harm). A 2025 retrospective study of 197 pregnant patients found 20% azelaic acid was more effective than topical erythromycin or clindamycin for acne, with no difference in adverse effects — making it the preferred first-line for pregnancy acne and melasma when retinoids are off the table. **Niacinamide** (vitamin B3) is a water-soluble ingredient with a well-established safety profile. The CIR Expert Panel found no stinging at concentrations up to 10%, no irritation, no sensitization, and no photosensitization. It is not associated with retinoid-like purging, photosensitivity, or barrier disruption. No specific pregnancy safety concerns have been identified in the literature. **Hyaluronic acid** is a naturally occurring glycosaminoglycan present in the body's own connective tissue. The CIR Expert Panel reviewed hyaluronic acid, potassium hyaluronate, and sodium hyaluronate and found no toxicity, sensitization, genotoxicity, developmental toxicity, or carcinogenicity. Topical application at cosmetic concentrations results in minimal systemic exposure. No pregnancy concerns have been identified. **Vitamin C (L-ascorbic acid and stable derivatives)** is an essential nutrient naturally present in the body. Topical ascorbic acid and its derivatives are classified safe as used by the CIR. No pregnancy-specific safety concerns have been identified. L-ascorbic acid's requirement for a pH below 3.5 formulation may mean it causes more transient stinging — pregnancy can alter skin sensitivity — but this is a tolerability consideration, not a safety concern. **Benzoyl peroxide (topical, limited use)** is an OTC acne drug active. The American College of Obstetricians and Gynecologists (ACOG) has suggested OTC topical products containing benzoyl peroxide for use during pregnancy when needed, noting that minimal systemic absorption means it is not expected to increase birth defect risks when used as directed. Approximately 5% of the applied dose is metabolized to benzoic acid and renally excreted. FDA classified BPO pregnancy risk category C under the old system, which means adequate human studies are lacking — not that it is known to be harmful. **Glycolic acid and mandelic acid (AHAs) in moderation** are considered low-risk for leave-on consumer products at standard concentrations (up to 10%). Low systemic absorption through intact skin is the primary basis for this position. One clinical review of skin care safety during pregnancy (Bozzo et al. 2011) specifically addressed this category. High-concentration glycolic acid peels should be avoided — systemic absorption risk increases with concentration, and there is no meaningful clinical benefit to using professional-concentration AHAs during pregnancy that outweighs precautionary concern.

• Study Retrospective analysis of 197 pregnant patients found 20% azelaic acid more effective than 4% erythromycin or 1% clindamycin for pregnancy acne (superior IGA improvement and patient satisfaction); no difference in adverse effects. Azelaic acid is naturally occurring in human plasma; approximately 4% of a topical dose is systemically absorbed, within the normal endogenous range. ⁴
• CIR Niacinamide and niacin were assessed safe as used in cosmetic formulations; clinical testing showed no stinging at concentrations up to 10%, no irritation at concentrations up to 5%, no sensitisation, no photosensitisation, and non-carcinogenicity in rodent studies. ⁵
• CIR Hyaluronic acid, potassium hyaluronate, and sodium hyaluronate are safe as used in cosmetic formulations; no toxicity, sensitization, genotoxicity, developmental toxicity, or carcinogenicity was identified in a comprehensive CIR safety assessment. ⁶
• CIR L-ascorbic acid and its cosmetically used derivatives are safe as used in cosmetic products; the ingredient is not carcinogenic in either sex of rats or mice (NTP data) and does not present a risk of skin sensitisation. ⁷
• Review The American College of Obstetricians and Gynecologists (ACOG) has suggested OTC topical products containing benzoyl peroxide for use during pregnancy, if needed; because topical medications result in minimal systemic absorption, BPO is not expected to increase birth defect risks or pregnancy complications when used as directed. ⁸
• Study Topical salicylic acid in cosmetic/acne products has low systemic absorption through intact skin; it is unlikely to pose significant risk to a developing baby at the concentrations used in typical cosmetic and OTC acne products. ⁹
• Study Salicylic acid peels should be avoided or used with caution during pregnancy; glycolic acid and lactic acid peels are considered safer alternatives for chemical exfoliation during pregnancy. ¹⁰

One honest caveat This category reflects clinical consensus and regulatory positions, not controlled RCTs in pregnant women. 'Generally considered safe' means low known risk and broad expert support — not a zero-risk guarantee. Skin sensitivity can change during pregnancy, so patch testing any new active is sensible regardless of safety category.

Several actives are widely marketed as 'pregnancy-safe' alternatives — particularly bakuchiol, which is branded as a 'natural retinol alternative safe for pregnancy.' This framing requires correction. **Bakuchiol** is not a retinoid; it is a meroterpene phenol structurally unrelated to vitamin A, and it does not carry retinoid teratogenicity risk. However, the 'pregnancy-safe' marketing claim goes one step further than the evidence allows — it implies affirmative safety when what actually exists is an absence of the retinoid concern. No human safety or pharmacokinetic data for bakuchiol in pregnancy has been published in peer-reviewed literature. The source plant Psoralea corylifolia contains psoralens (phototoxic furocoumarins) structurally distinct from bakuchiol; purified bakuchiol is separated from these, but formulation-specific purity is not uniformly verified. No CIR safety assessment for bakuchiol exists. The appropriate guidance is: bakuchiol is not expected to carry retinoid teratogenicity risk, but pregnancy safety has not been established. Consult your doctor or midwife before use. **Kojic acid** has documented contact sensitization risk in general use (a higher rate than gentler brighteners), and the available animal carcinogenicity data requires thoughtful regulatory scrutiny even though SCCS concluded topical use at 1% is safe for the general population. No specific human pregnancy safety data has been published. Given the absence of data and the known sensitization profile, avoidance during pregnancy is the conservative position. **Tranexamic acid (topical)** is a pharmaceutical agent with an established safety profile for oral and IV use. Topical cosmetic use at 2–5% is well-tolerated in the general population, and multiple clinical trials at these concentrations report no significant adverse events. However, no controlled pregnancy safety data exists for topical cosmetic tranexamic acid. The antifibrinolytic blood clot risk from oral TXA is dose- and route-dependent and does not transfer to topical cosmetic use; nonetheless, the absence of pregnancy-specific topical safety data means this falls in the 'insufficient data' category. Discuss with your prescriber if you are using or considering tranexamic acid. **Alpha-arbutin** is a hydroquinone glucoside. At cosmetic concentrations (≤2% face), the EU SCCS has assessed the margin of safety from hydroquinone release as acceptable for the general population. However, no pregnancy-specific safety data exists. Because alpha-arbutin can release small amounts of hydroquinone — a restricted/regulated skin lightener — the precautionary position is avoidance during pregnancy pending specific safety data. No controlled trials of alpha-arbutin in pregnancy have been published.

One honest caveat The absence of published pregnancy safety data for bakuchiol, kojic acid, tranexamic acid, and alpha-arbutin is not proof of danger. It simply means these ingredients have not been studied in pregnant populations. In a regulatory and ethical environment where such studies are not conducted, this is the expected state. The conservative choice is to stick with the well-characterized safe category during pregnancy. If a specific ingredient is important to your regimen, discuss it with your obstetrician rather than relying on marketing language.

Salicylic acid guidance during pregnancy varies by concentration and application type, and it is worth stating clearly because consumer products span a wide range. Low-percentage (0.5–2%) leave-on OTC acne products: considered low-risk by some authorities. Systemic absorption through intact skin at these concentrations is minimal. A 2011 review in Canadian Family Physician specifically addressed skin care products during pregnancy and categorized low-percentage topical salicylic acid as unlikely to pose significant risk at concentrations used in typical cosmetic and OTC acne products. Salicylic acid peels and high-concentration formulations: should be avoided during pregnancy. The precautionary concern relates to potential salicylate accumulation with large-area or high-dose use — salicylism (systemic salicylate toxicity) is documented with high-concentration topical applications to large body surface areas. Practical guidance: low-percentage spot treatment (0.5–2%) is a reasonable option for pregnancy acne when azelaic acid is not available or not effective. High-concentration products, body-area application, and professional peels should be deferred. Consult your physician.

• Study Topical salicylic acid in cosmetic/acne products has low systemic absorption through intact skin; it is unlikely to pose significant risk to a developing baby at the concentrations used in typical cosmetic and OTC acne products. ⁹
• Study Salicylic acid peels should be avoided or used with caution during pregnancy; glycolic acid and lactic acid peels are considered safer alternatives for chemical exfoliation during pregnancy. ¹⁰

Every pregnancy is different. The guidance in this article is based on published research, regulatory safety assessments, and clinical guidelines — but it is not a substitute for individualized medical advice. Skin conditions including acne and melasma can flare during pregnancy due to hormonal changes, and your treating physician or obstetrician is the right person to evaluate your full skincare routine in context. Key practical points: stop retinoids immediately; azelaic acid is typically the first-line prescription option dermatologists recommend for pregnancy acne and melasma; for over-the-counter brightening and hydration, niacinamide, hyaluronic acid, and vitamin C are widely used without concerns; sunscreen is non-negotiable (UV exposure worsens pregnancy melasma). If you are unsure about a specific product ingredient, the conservative approach is to avoid it until you can check with your provider.

Can I use retinol while pregnant?

No — all topical retinoids (retinol, retinal, tretinoin, retinyl palmitate, HPR) are recommended against during pregnancy. The recommendation is precautionary: the known potent teratogenicity of oral synthetic retinoids, combined with a large epidemiological study linking high supplemental oral vitamin A to birth defects, established the caution. Two large studies (including a Nordic registry of 3.8 million births) found no statistically significant increase in birth defects from topical retinoid exposure, but current clinical guidance is to avoid during pregnancy and while planning to conceive. Stop retinoids when you begin trying to conceive. ¹²³

Is azelaic acid safe during pregnancy?

Azelaic acid is one of the few actives where dermatologists and obstetricians broadly give an affirmative yes, not just a low-risk qualifier. It was FDA Pregnancy Category B (animal studies showed no fetal harm; human controlled trials are not available for any topical active). Crucially, azelaic acid is a naturally occurring substance already in human plasma — even the approximately 4% that absorbs systemically falls within the normal physiological range. A 2025 retrospective study of 197 pregnant patients found 20% azelaic acid more effective than topical erythromycin or clindamycin for pregnancy acne, with no difference in adverse effects. It is typically the first-line recommendation for both pregnancy acne and pregnancy melasma when retinoids are off the table. ⁴

Is bakuchiol safe during pregnancy?

Bakuchiol does not carry retinoid teratogenicity risk — it is structurally unrelated to vitamin A and is not a retinoid. The widespread 'pregnancy-safe retinol alternative' marketing claim reflects the absence of this specific risk, not affirmative evidence of safety. No human safety or pharmacokinetic data for bakuchiol in pregnancy has been published in peer-reviewed literature. No CIR safety assessment for bakuchiol exists. The source plant Psoralea corylifolia contains psoralens (phototoxic compounds) separate from bakuchiol; purified bakuchiol is distinct, but formulation purity is not uniformly verified. If you want to use bakuchiol during pregnancy, discuss it with your obstetrician — but it is not the established 'safe' alternative that marketing suggests.

Can I use vitamin C serum while pregnant?

Yes — topical vitamin C (L-ascorbic acid and stable derivatives) is widely considered safe during pregnancy. It is an essential nutrient naturally present in the body, and the CIR Expert Panel assessed L-ascorbic acid and its cosmetically used derivatives as safe for use in cosmetic products. No pregnancy-specific safety concerns have been identified. The main practical note is that L-ascorbic acid requires a low-pH formulation (below pH 3.5) that can cause transient stinging — pregnancy can increase skin sensitivity, so some people find they need to reduce concentration or frequency. If that's the case, stable derivatives like sodium ascorbyl phosphate or ascorbyl glucoside at neutral pH are tolerated more easily. ⁷

What about benzoyl peroxide for pregnancy acne?

Benzoyl peroxide has support from ACOG for limited OTC topical use during pregnancy when needed. Minimal systemic absorption — approximately 5% of the applied dose is metabolized to benzoic acid and renally excreted — is the basis for its favorable pregnancy risk profile. It is not expected to increase birth defect risks when used as directed. Start at 2.5% (the evidence shows it is as effective as 5–10% with less irritation) and use it for spot treatment rather than full-face daily application. The benzene degradation concern that made headlines in 2024 is temperature-dependent — store products at room temperature, avoid hot cars or bathrooms, and the risk from standard products under normal conditions is very low per FDA's 2025 testing of 95 products. ⁸

Is salicylic acid safe during pregnancy?

It depends on concentration and application. Low-percentage (0.5–2%) leave-on OTC products for spot treatment are considered low-risk because systemic absorption through intact skin at these concentrations is minimal. A 2011 review specifically addressing skin care products during pregnancy categorized low-percentage topical salicylic acid as unlikely to pose significant risk. Salicylic acid peels and high-concentration formulations should be avoided — potential salicylate accumulation with large-area or high-dose use is the concern. Practical bottom line: a 2% salicylic acid spot treatment is a reasonable option when azelaic acid is not available or not effective, but check with your doctor first. ⁹¹⁰

Is glycolic acid or mandelic acid safe to use while pregnant?

Consumer-concentration AHAs (up to 10%) in leave-on products are generally regarded as low-risk based on minimal systemic absorption from intact skin. Mandelic acid — the gentler AHA because of its larger molecular weight — is often specifically mentioned in pregnancy skincare discussions for this reason. The guidance for professional glycolic acid peels (20–70%) is different: the combination of higher concentration, professional application technique, and larger treatment area increases potential systemic exposure, and most sources recommend avoiding professional peels during pregnancy. For daily skincare at consumer concentrations, apply SPF religiously — AHAs increase UV sensitivity, and pregnancy melasma is worsened by sun exposure. ⁹

What skincare ingredients should I use for pregnancy melasma?

Pregnancy melasma (the 'mask of pregnancy') has limited treatment options because retinoids and hydroquinone are off the table. The evidence-supported first-line options are azelaic acid (most strongly supported for pregnancy — both effective and specifically studied in a pregnancy population), niacinamide (4–5% reduces melanin transfer and is well tolerated), vitamin C (tyrosinase inhibition and antioxidant photoprotection), and broad-spectrum SPF 50 every day (non-negotiable — UV re-stimulates melanin production and undermines any brightening active). Many cases of pregnancy melasma resolve postpartum; starting aggressive treatment during pregnancy is rarely necessary. Discuss your situation with a dermatologist who manages pregnant patients. ⁴⁵

1. 1

   Teratogenicity of high vitamin A intake

   Rothman KJ, Moore LL, Singer MR, Nguyen US, Mannino S, Milunsky A · New England Journal of Medicine 333(21):1369-73 · 1995

2. 2

   Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study

   Panchaud A, Csajka C, Merlob P, Schaefer C, Berlin M, De Santis M, et al. · Journal of Clinical Pharmacology 52(12):1844-51 · 2012

3. 3

   Topical retinoid use in women of reproductive age and risk of major congenital malformations in exposed pregnancies: a Nordic cohort study

   Refsum E, Furu K, Cesta CE, Nørgaard M, Wittström F, Zoega H, Ulrichsen SP, Cohen JM · British Journal of Dermatology 194(4):640-647 · 2026

4. 4

   Retrospective Analysis of Efficacy and Side Effects of Topical 4% Erythromycin Versus 1% Clindamycin Versus 20% Azelaic Acid During Pregnancy

   Hasanbeyzade S · Journal of Cosmetic Dermatology · 2025

5. 5

   Final report of the safety assessment of niacinamide and niacin

   Cosmetic Ingredient Review Expert Panel · International Journal of Toxicology 24 Suppl 5:1-31 · 2005

6. 6

   Final report of the safety assessment of hyaluronic acid, potassium hyaluronate, and sodium hyaluronate

   Becker LC, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW; Cosmetic Ingredient Review Expert Panel; Andersen FA · International Journal of Toxicology 28(4 Suppl):5-67 · 2009

7. 7

   Final report of the safety assessment of L-Ascorbic Acid, Calcium Ascorbate, Magnesium Ascorbate, Magnesium Ascorbyl Phosphate, Sodium Ascorbate, and Sodium Ascorbyl Phosphate as used in cosmetics

   Elmore AR · International Journal of Toxicology 24 Suppl 2:51-111 · 2005

8. 8

   Topical Acne Treatments — MotherToBaby Fact Sheet

   Organization of Teratology Information Specialists (OTIS) · NCBI Bookshelf · 2023

9. 9

   Safety of skin care products during pregnancy

   Bozzo P, Chua-Gocheco A, Einarson A · Canadian Family Physician 57(6):665-667 · 2011

10. 10

    A review of the safety of cosmetic procedures during pregnancy and lactation

    Trivedi MK, Kroumpouzos G, Murase JE · International Journal of Women's Dermatology 3(1):6-10 · 2017